Loading…
Loading…
EHAB (Enhabit, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
EHAB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for EHAB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for EHAB and 80,000+ other tickers.
See exactly how EHAB's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for EHAB and 80,000+ other tickers.
Enhabit, Inc. operates as a U.S.-based provider of home healthcare and hospice services. Its comprehensive home health division offers various services, such as patient education, pain management, wound care (including dressing changes), cardiac rehabilitation, infusion therapy, pharmaceutical administration, and expert observation and assessment. The company specializes in managing chronic conditions like diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and persistent pain. Additionally, Enhabit…
DALLAS--(BUSINESS WIRE)--Enhabit, Inc., a leading home health and hospice provider, today announced that Dale Clift has been appointed president and CEO, following the successful completion of the company's acquisition by Kinderhook Industries. Clift succeeds Barb Jacobsmeyer, former president and CEO of Enhabit, who previously announced her intention to step down upon the appointment of a successor. Clift brings decades of leadership experience in home health and hospice care. He previously se.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Enhabit (EHAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enhabit, Inc. (NYSE: EHAB - Get Free Report) has been given a consensus recommendation of "Hold" by the nine ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws